BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:59 PM
 | 
Oct 03, 2012
 |  BC Extra  |  Top Story

Celgene receives option to acquire VentiRx

VentiRx Pharmaceuticals Inc. (Seattle, Wash.) granted Celgene Corp. (NASDAQ:CELG) an exclusive option to acquire the company following Phase II data of VTX-2337 in ovarian or head and neck cancer. VentiRx will receive $35 million up...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >